KRAS and colorectal carcinoma: For CRC metastases, the Krikelis et al. study including 58 stage IV patients found no correlation between SUV max and KRAS mutations, [65] Kawada et al., to minimize bias due to the partial volume effect, only considered tumors larger than 10 mm in diameter and showed that the KRAS mutation can be reliably predicted with an accuracy of 71.4% using a SUVmax threshold greater than 6.0 [66].